This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
Title of project or programme
Luminescent polymers for in vivo imaging of amyloid signatures
Principal Investigators of project/programme grant
| Title | Forname | Surname | Institution | Country |
| Dr | Magnus | Fredriksson | Sweden | |
Address of institution of lead PI
| Institution | |
| Street Address | SE-581 83 |
| City | |
| Postcode |
Country
Sweden
Source of funding information
European Commission
Total sum awarded (Euro)
4978094
Start date of award
01-11-2009
Total duration of award in months
36
The project/programme is most relevant to
- Alzheimer’s disease and other dementias
- Prion disease
Keywords
Research abstract in English
In this project we seek to develop new smart imaging molecular tools for combating neurodegenerative diseases such as Alzheimer.
The LUPAS project seeks to bridge the gap between diagnosis and treatment of both Alzheimer disease and prion diseases. By developing novel agents and methods for diagnostic imaging of accumulations of misfolded proteins so called amyloid plaque it is possible to improve quality of diagnosis as well as facilitate monitoring and understanding of the disease progression. The novel molecular imaging tools are based on luminescent conjugated polymers, LCPs, a material normally used for electronic applications, such as light emitting diodes (LEDs). It was discovered by the researchers forming the LUPAS consortium that these molecules bind effectively to amyloid plaques. Through the specific a luminescent fingerprint of the LCPs, the amyloid plaques can easily be visualized and recognized. Moreover, the molecular scaffolds will be tested as therapeutically active agents for prevention of protein aggregation diseases and could possibly facilitate treatment of AD and prionoses in the future.
Lay summary
Luminescent polymers for in vivo imaging of amyloid signatures
Investments > €500k
Sweden
Alzheimer’s disease & other dementias|Prion disease
2011
